Last Updated : May 8, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda | Pembrolizumab | Nonsquamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | recurrent, or metastatic cervical cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Esophageal carcinoma, gastroesophageal junction adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Active | |||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
| Keytruda | pembrolizumab | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn |
Last Updated : May 8, 2024